// App-Quantinova.ai

103 : Pembrolizumab to augment response to CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).

Researchers

Presenter

  • Shannon L. Maude

Principal Investigators

  • George E Hucks

  • Alix Eden Seif

  • Mala Kiran Talekar

  • David T. Teachey

  • Diane Baniewicz

  • Colleen Callahan

  • Vanessa Gonzalez

  • Farzana Nazimuddin

  • Minnal Gupta

  • Noelle V. Frey

  • David L. Porter

  • Bruce L Levine

  • Jan J. Melenhorst

  • Simon F. Lacey

  • Carl H. June

  • Stephan A. Grupp

Medical Centers

  • Cancer Immunotherapy Program, The Children's Hospital of Philadelphia, Philadelphia, PA

  • Childrens Hospital of Philadelphia, Philadelphia, PA

  • Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Cancer antigen 15-3

  • Programmed cell death protein 1

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • Pembrolizumab

  • CTL019

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02374333

  • NCT02906371

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved